Pricing Log in Create free account

Dermata Therapeutics, Inc. (DRMA) vs Liminatus Pharma Inc. (LIMN)

Dermata Therapeutics, Inc. and Liminatus Pharma Inc. are both Biotechnology companies. Dermata Therapeutics, Inc. and Liminatus Pharma Inc. are of similar size ($4.5M and $4.3M). Across the 9 metrics below, Dermata Therapeutics, Inc. leads on 6 and Liminatus Pharma Inc. on 3.

Valuation

Metric DRMA LIMN Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B 0.99 9.79 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.03 n/m 0.64
EV/Sales n/m n/m 9.21
Earnings yield (510.47%) (773.03%) (33.15%)
Free cash flow yield (232.27%) (135.00%) (25.50%)

Profitability

Metric DRMA LIMN Biotechnology median
Gross margin — — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (183.89%) 294.43% (56.36%)
Return on assets (139.93%) (471.47%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DRMA LIMN Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 89.84% (112.19%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric DRMA LIMN Biotechnology median
Debt to equity 0.00 4.80 0.00
Current ratio 2.81 1.12 4.72
Net debt to EBITDA 0.97 (0.37) 0.96

Dividend

Metric DRMA LIMN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DRMA LIMN Biotechnology median
Market cap 4.51m 4.32m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack